Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNX-102 SL in Fibromyalgia (RALLY)
NCT04508621Phase 3Completed
- Sponsor
- Tonix Pharmaceuticals
- Start
- Jul 2020
- Primary completion
- Nov 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in fibromyalgia (FM) comparing TNX-102 SL with Placebo (2 arms). Primary endpoint: Change From Baseline in Numerical Rating Scale Weekly Average of Daily Self-reported Average Pain Severity at 14 weeks. Started Jul 2020; status: completed.
02
Drugs
Tonmya
03
Conditions
fibromyalgia (FM)
Beyond the preview
Go deeper on NCT04508621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04508621.